SpineX begins patient enrolment in SCONE Clinical Trial

SpineX Inc., a clinical stage bioelectric medtech company, has announced that the first patient has been enrolled in a trial evaluating the SCONE Device. The trial will evaluate the safety and effectiveness of the device for the treatment of Neurogenic bladder.

Neurogenic bladder is the most common comorbidity that people suffer from after paralysis, and has the largest impact on their quality of life. “For a person in a wheelchair, the inability to walk is the most obvious functional loss, but the impact on quality of life due to neurogenic bladder is unparalleled,” said Dr. Evgeniy Kreydin, MD, co-founder, SpineX Inc., and assistant professor at University of Southern California, Los Angeles.

People living with neurogenic bladder have to deal with lost sensation of bladder fullness, low bladder capacity, frequent urination cycles, and uncontrolled urine leakage. SCONE therapy is designed to treat each of these symptoms, thus having an impact on quality of life.

“The initiation of the SCONE trial is an important milestone in bringing the world’s first non-invasive treatment modality for neurogenic bladder to market,” said Dr. Parag Gad, PhD, chief executive officer of SpineX Inc. “We are committed to transforming bladder management into a catheter free and leak free world.”